Ascendis Presents Week 104 Approach Trial Data for YUVIWEL

With a Marketing Authorisation Application under EMA review and a regulatory decision anticipated in Q4 2026, Ascendis Pharma's two-year dataset for navepegritide (YUVIWEL) arrives at a consequential moment for the company's European filing strategy. The Week 104 open-label extension data from the ApproaCH Trial will be presented orally at ISDS 2026 in Toronto on August 28, with Carlos Bacino, M.D., of Baylor College of Medicine and Texas Children's Hospital delivering the findings.

The dataset covers children with achondroplasia treated with once-weekly TransCon CNP, a prodrug of C-type natriuretic peptide designed to sustain continuous CNP receptor exposure and counteract overactive FGFR3 signaling. Reported outcomes span linear growth, lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning, with a safety and tolerability profile described as comparable to placebo and a low rate of injection site reactions.

For regulatory affairs leads tracking the EMA dossier, the 104-week horizon matters: long-term efficacy and safety data in pediatric rare disease submissions are subject to close scrutiny under ICH E11 and the EMA's pediatric investigation plan framework. The FDA approved YUVIWEL in February 2026 for pediatric patients aged two years and older with achondroplasia with open epiphyses, establishing a precedent the EMA review team will weigh against its own evidentiary standards.

A companion poster, also presented across the August 26-29 conference period, addresses a methodological point with direct relevance to health technology assessment submissions: a Number Needed to Harm analysis for injection site reactions in contexts where indirect treatment comparison is not suitable. That analysis, authored by Manoj Chevli et al., signals Ascendis is building the comparative safety evidence base ahead of anticipated payer negotiations in European markets.

Achondroplasia affects an estimated 250,000 people worldwide; its systemic FGFR3 variant drives muscular, neurological, and cardiorespiratory complications beyond skeletal dysplasia, broadening the clinical endpoints regulators and payers are expected to scrutinize across the product's lifecycle.

The EMA decision anticipated in Q4 2026 will test whether the 104-week efficacy and safety profile presented at ISDS translates into a label that matches the scope of the FDA approval.

Source: Ascendis Pharma A/S via GlobeNewswire, August 25, 2026.